Navigation Links
Human Genome Sciences Reports Positive Long-Term Data for BENLYSTA(TM) (Formerly LymphoStat-B(R)) in Patients With Active Systemic Lupus Erythematosus
Date:6/11/2009

o worsening in Physician's Global Assessment. This response rate is the primary efficacy endpoint in the ongoing pivotal Phase 3 clinical trials.

About BENLYSTA (belimumab)

BENLYSTA is a human monoclonal antibody that specifically recognizes and inhibits the biological activity of B-lymphocyte stimulator, or BLyS(R). BLyS is a naturally occurring protein discovered by HGS that is required for the development of B-lymphocyte cells into mature plasma B cells. Plasma B cells produce antibodies, the body's first line of defense against infection. In lupus and certain other autoimmune diseases, elevated levels of BLyS are believed to contribute to the production of autoantibodies - antibodies that attack and destroy the body's own healthy tissues. The presence of autoantibodies appears to correlate with disease severity. Preclinical and clinical studies demonstrate that BLyS antagonists can reduce autoantibody levels and help control autoimmune disease activity.

About the Collaboration with GSK

In August 2006, HGS and GSK entered into a definitive co-development and co-commercialization agreement under which HGS has responsibility for conducting the BENLYSTA Phase 3 trials, with assistance from GSK. The companies will share equally in Phase 3/4 development costs, sales and marketing expenses, and profits of any product commercialized under the agreement.

About Systemic Lupus Erythematosus

Systemic lupus erythematosus (SLE) is a chronic, life-threatening autoimmune disease. Approximately 1.5 million people in the United States and approximately 5 million worldwide suffer from various forms of lupus, including SLE. Lupus can occur at any age, but appears mostly in young people ages 15 to 45. About 90 percent of those diagnosed with lupus are women. African-American women are about three times more likely to develop lupus, and it is also more common
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Printing New Organs: Foundation Funds Medical Technology That Replicates Human Tissue
2. New MIT radio chip mimics human ear
3. deCODE Study Shows Complex Interplay of the Human Biological Clock With Height, Weight and Disease
4. Human Genome Sciences and Novozymes Announce Amendment to Albumin Fusion License Agreement
5. Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments
6. FDA has Granted HUD (Humanitarian Use Device) Designation to ITGIs Pericardium Covered Stents, Over and Under(R) and Aneugraft(R), for Treatment of Perforations and Dissections of Native Coronary Arteries and Saphenous Vein Grafts
7. STEMCELL Technologies Introduces a New Animal Component-Free, Serum-Free Medium for Culturing Human Mesenchymal Stem Cells
8. CEL-SCI Presents Data at Prestigious Medical Conference Demonstrating That Its L.E.A.P.S. Technology Stimulates Maturation of Human Blood Cells Into Dendritic Cells Suggesting Potential for Prevention and Treatment of Infectious Disease
9. Human Genome Sciences to Sponsor Conference Call to Discuss First Quarter 2009 Financial Results
10. The Journal of Cardiac Failure Publishes Results From Celladon Corporations First-in-Human Phase 1/2 Clinical Trial in Advanced Heart Failure
11. ArunA Biomedical Announces Commercial Release of its Human Embryonic Stem Cell Derived Mesenchymal Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... GenoCAD , a platform leveraging the ... announced the formation of its new board of advisors ... a broad range of experience in the biotechnology, pharmaceutical, ... , Jimmy Roussel, Entrepreneur in Residence at The New ... technology and marketing. He has served in operations roles ...
(Date:6/1/2015)... 2015 Research and ... addition of the "Oxidative Stress Assay ... Type (Indirect, Enzyme-based, Reactive Oxygen Species (ROS)-based), ... - Global Forecast to 2020" report ... http://photos.prnewswire.com/prnh/20130307/600769) , The global oxidative ...
(Date:6/1/2015)... GenomeDx Biosciences today announced that ... classified various subtypes of bladder cancer based ... including one type associated with resistance to ... has potential as a tool to predict ... with muscle-invasive bladder cancers (MIBC). The study ...
(Date:6/1/2015)... 2015  Novartis is highlighting data from an ... investigational chimeric antigen receptor (CAR) T cell therapy, ... specific types of hard-to-treat non-Hodgkin lymphoma. Findings from ... Pennsylvania,s Perelman School of Medicine (Penn) in adults ... lymphoma (DLBCL) and follicular lymphoma (FL) found an ...
Breaking Biology Technology:GenoCAD Announces New Board of Advisors, Improves Protein Expression Using Custom Gene Synthesis 2GenoCAD Announces New Board of Advisors, Improves Protein Expression Using Custom Gene Synthesis 3Oxidative Stress Assay Market 2015 - Global Forecast to 2020 2GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 2GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 3GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 2Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 3Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 5Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 6
... 20 At a meeting of the Board,of Directors of ... of fifty cents($0.50) per share on the outstanding shares of ... of record at the close of business,on December 12, 2008. ... of the world,s largest research-driven pharmaceutical and,health care products companies. ...
... 20 Sigma-Aldrich (Nasdaq: SIAL ),announced today ... iScale,Oligos(TM) siRNA. MISSION(R) In VIVO QUALITY and iScale Oligos(TM) ... next step in their RNAi,research with the highest purity ... These siRNA are believed to be well suited to ...
... Nephros, Inc. (Amex: NEP ), a medical device company developing and marketing ... on its operations and strategy. , , Recent ... , Appointed James Scibetta Chairman of ... III President and CEO , Submitted 510k for ...
Cached Biology Technology:Sigma-Aldrich Introduces MISSION(R) In VIVO QUALITY and iScale Oligos(TM) siRNA, a Superior Quality siRNA Designed for RNAi Research in Animal Models 2Nephros Provides Corporate Update 2Nephros Provides Corporate Update 3Nephros Provides Corporate Update 4Nephros Provides Corporate Update 5Nephros Provides Corporate Update 6Nephros Provides Corporate Update 7
(Date:4/20/2015)... 20, 2015 Huntington Memorial Hospital is the ... a new miniaturized, wireless monitoring sensor to manage heart ... and only FDA-approved heart failure monitoring device that has ... by physicians to manage heart failure. The ... in the pulmonary artery (PA) during a non-surgical procedure ...
(Date:4/14/2015)... YORK , April 14, 2015  HYPR ... IDentity Online (FIDO ® ) Alliance tm , ... specifications. FIDO members commit to share technology and ... methods that are interoperable, more secure and private, ... enable biometric identity verification that protects sensitive user ...
(Date:4/13/2015)... a leading cloud-based consumer engagement platform that provides trusted ... communities around health and wellness, announced today the launching ... The ... vehicle to receive validated health information from consumers. ... will allow higi,s trusted partners, on a user opt-in ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3
... a class of small molecules known as microRNA have been ... in most animal and plant species. A new study now ... a hallmark of alcohol abuse and dependence. Researchers supported by ... the findings in the July 31 issue of the journal ...
... July 29, 2008 Two Fortune 500 oil companies ... Engineering at the University of Houston. The funds, from ... Corp., will provide support for a new undergraduate program ... by the Texas Higher Education Coordinating Board this fall. ...
... or cold is not only uncomfortable, it can be ... many years now, scientists have understood the molecular mechanisms ... extremely high temperatures that directly trigger heat sensor proteins ... understood is how animals sense very small temperature differences ...
Cached Biology News:MicroRNA implicated as molecular factor in alcohol tolerance 2Energy industry leaders commit $1.6M to UH petroleum program 2Energy industry leaders commit $1.6M to UH petroleum program 3Summer heat too hot for you? What is comfortable? 2Summer heat too hot for you? What is comfortable? 3